233 results
Page 3 of 12
6-K
EX-99.1
en040 249dppqy8nopq
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.2
dhwp4kdl5er4k
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.1
vyr8owblomu70qztvlbj
21 Sep 23
SciSparc Announces 1-for-26 Reverse Share Split
6:31am
6-K
grcfk29p7h imtodkz
21 Sep 23
SciSparc Announces 1-for-26 Reverse Share Split
6:31am
6-K
EX-99.1
n8072uhyhd2
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
EX-99.1
0jn31jdl k437c
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
EX-99.2
bpkvjolbbr445yru1z
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
EX-99.2
stednuhr10qb5bb6y
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
6-K
EX-99.1
zru3xzx
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
6-K
EX-1.1
x0qv7lipeh1sg lr
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
424B5
cs4d60rxq666xffj7use
14 Aug 23
Prospectus supplement for primary offering
9:14am
424B3
1pud6fmxcxyc
10 Aug 23
Prospectus supplement
6:32am
6-K
EX-99.1
0smhbzz40c lq
9 Aug 23
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
7:30pm
6-K
EX-99.1
njxv u0jvykc9v7u5c
2 Aug 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
kp4c407ae0fd3jz
17 Jul 23
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
8:00am
6-K
EX-99.1
820q3f04grx
30 Jun 23
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
4:10pm
6-K
cf7ujrap 1ql07h
26 Jun 23
Report of Foreign Private Issuer
4:04pm
6-K
EX-99.1
0atgw6m z91qv
21 Jun 23
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
9:08am
6-K
EX-99.1
5zg2btr
16 Jun 23
Report of Foreign Private Issuer
9:09am
6-K
EX-99.1
aui0ho8qqqfa8y8fr3wc
12 Jun 23
SciSparc Grants an Exclusive License for the Sales of CannAmideā¢ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
7:02am